Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy by A Morales et al.
We are concerned about this article, which was given to use by a pharmaceutical representative. Although the title makes it clear that these guidelines are to manage testosterone therapy, they could easily be construed as recommending therapy in a large proportion of the male elderly population.
Our understanding of clinical practice guidelines is that they result from a combination of expert opinion and published evidence, and are meant to suggest courses of action in speci®c circumstances. As discussed by Hayward and Laupacis,`...relatively few of the 1200 existing guidelines merit attention or application by typical clinicians. If practice guidelines are to facilitate high-quality care they must be developed and prescribed carefully.' 1 Hayward and Laupacis discuss an explicit process for the development of guidelines which might have been used to good effect in this case.
Clinical practice guidelines should have a carefully de®ned goal and target population, and make recommendations based on a comprehensive review of this topic, with grades applied to the available evidence. Bene®ts and possible harm of the guidelines should be discussed, and in a perfect world the guidelines would be validated through a pilot application. Another important factor is identi®ca-tion of the sponsoring bodies. In these guidelines, there is no summary of the published evidence for clinical effectiveness of testosterone supplementation, and no evidence relating low measured levels to clinical symptoms.
Their absence gives rise to the following questions: (1) In summary, we ®nd these clinical practice guidelines to be lacking in evidence and in a description of the process whereby they were developed. In our area they are being used by the manufacturers of testosterone to promote their product, and we fear that decisions based on these guidelines will not be suf®ciently evidence-based, cost-effective, or potentially bene®cial. Therapy for all older men with low testosterone levels could be construed as the recommendation of the guidelines. A more explicit approach could possibly have produced a truly useful decision tool in the clinical use of testosterone, especially the new, heavily promoted, oral agents.
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